Intra-Cellular Therapies (ITCI) Stock Forecast, Price & News

Intra-Cellular Therapies (NASDAQ:ITCI) Frequently Asked Questions

Is Intra-Cellular Therapies a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Intra-Cellular Therapies stock.
View analyst ratings for Intra-Cellular Therapies or view top-rated stocks.

When is Intra-Cellular Therapies' next earnings date?

Intra-Cellular Therapies is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Intra-Cellular Therapies.

How were Intra-Cellular Therapies' earnings last quarter?

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) announced its quarterly earnings data on Tuesday, May, 10th. The biopharmaceutical company reported ($0.78) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.14. The biopharmaceutical company had revenue of $35 million for the quarter, compared to analyst estimates of $33.52 million. Intra-Cellular Therapies had a negative trailing twelve-month return on equity of 53.93% and a negative net margin of 294.89%. The business's revenue for the quarter was up 120.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.65) EPS.
View Intra-Cellular Therapies' earnings history.

What price target have analysts set for ITCI?

7 brokers have issued twelve-month price targets for Intra-Cellular Therapies' shares. Their forecasts range from $40.00 to $70.00. On average, they anticipate Intra-Cellular Therapies' share price to reach $60.43 in the next year. This suggests a possible upside of 4.4% from the stock's current price.
View analysts' price targets for Intra-Cellular Therapies or view top-rated stocks among Wall Street analysts.

Who are Intra-Cellular Therapies' key executives?

Intra-Cellular Therapies' management team includes the following people:

• Dr. Sharon Mates Ph.D., Co-Founder, Chairman, CEO & Pres (Age 69, Pay $2.25M)
• Mr. Lawrence J. Hineline CPA, CPA, Sr. VP of Fin., CFO, Treasurer & Assistant Sec. (Age 66, Pay $791.01k) (LinkedIn Profile)
• Mr. Michael I. Halstead J.D., Exec. VP, Gen. Counsel & Sec. (Age 49, Pay $1.08M)
• Dr. Suresh K. Durgam M.D., Exec. VP & Chief Medical Officer (Age 53, Pay $1.03M) (LinkedIn Profile)
• Mr. Mark Neumann, EVP & Chief Commercial Officer (Age 59, Pay $1.01M) (LinkedIn Profile)
• Dr. Robert E. Davis Ph.D., Sr. VP & Chief Scientific Officer (Age 71)
• Mr. Juan Fernando Sanchez, VP of Corp. Communications & Investor Relations (Age 51)
• Ms. Karen Patruno Sheehy Esq., Sr. VP & Chief Compliance Officer (Age 60)
• Dr. Michael Olchaskey, Sr. VP & Head of Regulatory Affairs
• Mr. John A. Bardi, Sr. VP of Market Access, Policy & Gov. Affairs

Who are some of Intra-Cellular Therapies' key competitors?

Some companies that are related to Intra-Cellular Therapies include Horizon Therapeutics Public (HZNP), Genmab A/S (GMAB), Genmab A/S (GNMSF), Catalent (CTLT), UCB (UCBJF), Alnylam Pharmaceuticals (ALNY), Shiseido (SSDOY), BioMarin Pharmaceutical (BMRN), Viatris (VTRS), BeiGene (BGNE), Ono Pharmaceutical (OPHLF), Elanco Animal Health (ELAN), Biohaven Pharmaceutical (BHVN), Organon & Co. (OGN) and Teva Pharmaceutical Industries (TEVA).
View all of ITCI's competitors.

What other stocks do shareholders of Intra-Cellular Therapies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Sorrento Therapeutics (SRNE), Amarin (AMRN), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Synergy Pharmaceuticals (SGYP), Myovant Sciences (MYOV), Novavax (NVAX), Pfizer (PFE), AbbVie (ABBV) and Clovis Oncology (CLVS).

What is Intra-Cellular Therapies' stock symbol?

Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI."

Who are Intra-Cellular Therapies' major shareholders?

Intra-Cellular Therapies' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (8.26%), Wasatch Advisors Inc. (7.93%), BlackRock Inc. (6.86%), Wellington Management Group LLP (4.31%), Bellevue Group AG (3.64%) and Lord Abbett & CO. LLC (2.10%). Company insiders that own Intra-Cellular Therapies stock include Christopher D Alafi, Christopher D Alafi, Joel S Marcus, Lawrence J Hineline, Lawrence J Hineline, Mark Neumann, Michael Halstead, Rory B Riggs, Sharon Mates and Suresh K Durgam.
View institutional ownership trends for Intra-Cellular Therapies.

Which institutional investors are selling Intra-Cellular Therapies stock?

ITCI stock was sold by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., TimesSquare Capital Management LLC, Bellevue Group AG, Lord Abbett & CO. LLC, DCF Advisers LLC, Rhenman & Partners Asset Management AB, Clearbridge Investments LLC, and Nicholas Investment Partners LP. Company insiders that have sold Intra-Cellular Therapies company stock in the last year include Christopher D Alafi, Joel S Marcus, Lawrence J Hineline, Mark Neumann, Michael Halstead, Rory B Riggs, Sharon Mates, and Suresh K Durgam.
View insider buying and selling activity for Intra-Cellular Therapies or view top insider-selling stocks.

Which institutional investors are buying Intra-Cellular Therapies stock?

ITCI stock was bought by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Victory Capital Management Inc., Vanguard Group Inc., BlackRock Inc., Hood River Capital Management LLC, Invesco Ltd., Polar Capital Holdings Plc, and Suvretta Capital Management LLC.
View insider buying and selling activity for Intra-Cellular Therapies or or view top insider-buying stocks.

How do I buy shares of Intra-Cellular Therapies?

Shares of ITCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Intra-Cellular Therapies' stock price today?

One share of ITCI stock can currently be purchased for approximately $57.88.

How much money does Intra-Cellular Therapies make?

Intra-Cellular Therapies has a market capitalization of $5.46 billion and generates $83.80 million in revenue each year. The biopharmaceutical company earns $-284.13 million in net income (profit) each year or ($3.630010) on an earnings per share basis.

How many employees does Intra-Cellular Therapies have?

Intra-Cellular Therapies employs 512 workers across the globe.

What is Intra-Cellular Therapies' official website?

The official website for Intra-Cellular Therapies is www.intracellulartherapies.com.

How can I contact Intra-Cellular Therapies?

Intra-Cellular Therapies' mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The biopharmaceutical company can be reached via phone at (464) 440-9333, via email at [email protected], or via fax at 646-440-9334.